A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.

Kris V Kowdley,Raj Vuppalanchi,Cynthia Levy,Annarosa Floreani,Pietro Andreone,Nicholas F LaRusso,Roshan Shrestha,James Trotter,David Goldberg,Simon Rushbrook,Gideon M Hirschfield,Thomas Schiano,Yuying Jin,Richard Pencek,Leigh MacConell,David Shapiro,Christopher L Bowlus

Journal of Hepatology（2020）

引用 106|浏览130

暂无评分

摘要

•Novel treatments for PSC are an urgent unmet need.•This phase II study evaluated OCA in patients with PSC.•OCA 5–10 mg significantly reduced serum ALP levels at 24 weeks.•The safety profile of OCA was consistent with previous studies.

查看译文

关键词

Cholestasis,Farnesoid X receptor,Ursodeoxycholic acid

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要